



PATENT -- NO FEE
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: Application of)
PETER NASH ET AL)
Serial No.: 10/039,977)
Filed: January 8, 2002) Group Art Unit 1644
For: IMMUNOGEN ADHERENCE INHIBITOR)
AND METHOD OF MAKING AND)
USING SAME)
Case Docket No.: C150.12.3E)

THIRD DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants request that the patents and publications listed on the enclosed PTO Form 1449 be considered by the Examiner in the examination of this application.

The publications were made of record in Applicants' co-pending U.S. Patent Application Serial Nos. 10/025,567 and 10/038,260.

U.S. Patent Nos. 5,919,451 and 6,083,500 are of record in Applicants' PCT Application No. US 01/49588 corresponding to this application. U.S. Patent Nos. 5,919,451 and 6,083,500 are of record in this application.

Respectfully submitted,

PETER NASH ET AL

By Richard O. Bartz

Richard O. Bartz, Registration No. 20,468
Southdale Office Centre
6750 France Avenue South, Suite 350
Edina, MN 55435-1983
(952) 920-3959

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 18, 2003,
(Date of Deposit)

Richard O. BARTZ

Name of applicant, assignee, or Registered Rep.

Richard O. Bartz

Signature

September 18, 2003

Date of Signature

FORM PTO-1449 (REV. 7-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. C150.12.3E		SERIAL NO. 10/059,977	
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 24px; font-weight: bold;">O I P E</div> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 12px; font-weight: bold;">PATENT & TRADEMARK OFFICE</div> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 12px; font-weight: bold;">SEP 22 2003</div> </div>				LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)			
				APPLICANT Peter Nash et al FILING DATE January 8, 2003 GROUP 1644			
U.S. PATENT DOCUMENTS							
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
AA	5,741,489	04/21/1998	Pimental	424	157.1		
AB	6,217,865	04/17/2001	Hunchar	424	139.1		
AC							
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AL							
AM							
AN							
AO							
AP							
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	U.S. Patent Application Publication No. 2002/0012666 01/31/2002					
		Kuby et al, Immunology, second edition, pp. 85-96, 1994.					
	AS	Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.					
		Sugita-Konishi et al, Biosci Biotechnol Biochem 60(5): 986-8, May 96					
	AT	Yokoyama et al, Vaccine 16(4): 338-93, Feb. 1998.					
		Stryer et al, in Biochemistry, 3rd ed, W H Freeman Co., pp 51-53					
EXAMINER				DATE CONSIDERED 1998			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							